Business Wire

Xilam: H1 2017 Revenue: +67%

20.7.2017 19:00 | Business Wire

Jaa

Regulatory News:

The Xilam Group (Paris:XIL) posted consolidated H1 2017 revenue of EUR 9.239 million, an increase of 67%. The revenue breakdown is as follows:

In EUR 000   30.06.2017 (1)   30.06.2016   Change
New productions(2)   4,571   4,036   +13.3%
Catalogue   4,652   1,491   +212.0%
Other   16   21   -23.8%
Revenue   9,239   5,548   +66.5%

(1) unaudited data
(2) including subsidies and development

Solid growth

An excellent 1H performance was driven by the two main segments, Catalogue and New Productions.

Catalogue revenue tripled over the period, taking Xilam to the next level of its development. This increase stemmed from significant sales to both TV channels and digital platforms. In particular, sales to digital platforms jumped 149% to account for 40% of Catalogue revenue. Growth on the YouTube platforms is continuing its upward trajectory, with 1.12 billion views.

New Productions also performed well. This segment posted revenue of EUR 4.6 million, an increase of more than 13%, boosted by delivery of the latest episodes of Rolling with the Ronks! and further deliveries from season 5 of Oggy & the Cockroaches .

Strong international growth continues

International sales accounted for more than 67% of H1 revenue, an increase of over 194% during the period, thereby consolidating Xilam’s position as a global leader in the animation market.

Xilam content is now shown in more than 160 countries and in 600 million households.

Xilam has secured a number of major contracts for TV and on the leading digital platforms

On top of a solid revenue performance, the first half also saw the signing of several contracts that will further strengthen Xilam’s growth potential in the coming years:

  • The signing of a global distribution agreement with Amazon for its two flagship series Oggy & the Cockroaches and Zig & Sharko
  • The signing of an agreement with Netflix on three series that are currently in production
  • The signing of a new agreement with the Disney Channel for the broadcast of Oggy & the Cockroaches in Germany

Also in the first half of the year, Xilam signed a master toy licensing agreement with Lansay, which should gradually increase merchandising revenue.

Record full-year 2017 revenue expected

After a successful first half to the year, the pace of programme delivery will increase in the second half, to account for two-thirds of 2017 deliveries. Xilam is confident that it will post record revenue in 2017.

Season 5 of Oggy & the Cockroaches already a success

Global advance sales for the new season of Oggy & the Cockroaches were exceptional, and the first programmes will be launched in the third quarter of 2017, notably on Gulli in France, Discovery in Italy, Disney in Germany and Cartoon Network for the whole of Asia.

The quality of this series, along with the projected global distribution and multi-platform programming, will give the Oggy brand unprecedented exposure.

A step-up in production capacity

The upgraded studios that came on stream in 2016 (in Vietnam, Lyon and Angoulême) are now fully operational, enabling Xilam to confirm its ability to deliver about 350 half hours of programmes in 2017-2020.

New series in development

Production of the Mr Magoo series began in early 2017, and Xilam is currently developing a number of new series, including:

  • Coach me if you can
  • Zig & Sharko 3
  • Rolling with the Ronks! 2
  • Petit Méchant Loup [Little Bad Wolf]
  • The fabulous adventures of prince Moka

Coach me if you can and Zig & Sharko 3 are scheduled to enter production in the second half of 2017.

A stronger, more hands-on management team

To support its expansion, Xilam has strengthened its management structure with the arrival of François Bardoux (CFO), Morgann Favennec (Executive VP Development & Global Sales) and Nicolas Halftermeyer (SVP Marketing and Digital), and the internal promotion of François-Xavier de Maistre (Executive VP Organisation and Human Resources).

About Xilam

Xilam is one of Europe’s leading animation companies, producing and distributing original children’s and family entertainment content in both 2D and 3D formats across TV, film and digital media platforms.

Founded in 1995 by Marc du Pontavice, Xilam owns a catalogue of more than 2,000 animated episodes and 3 feature films including strong brands such as Oggy & the Cockroaches, Zig & Sharko, The Daltons, Rolling with the Ronks! and its first pre-school series, Paprika.

Broadcast in over 160 countries on all the major TV networks, these series are also breaking audience records on all the major digital platforms, including YouTube with over 2.2 billion views in 2016, ranking Xilam as one of the top global content providers in animation.

Xilam employs more than 400 people, including 300 artists, who are based across its four studios located in Paris, Lyon, Angoulême and Ho-Chi-Minh City in Vietnam.

Xilam is listed on Euronext Paris / Ticker: XIL / ISIN code: FR0004034072

Xilam is eligible for the PEA-PME investment scheme.

Contact information

Xilam
Marc du Pontavice – Chairman and CEO
François Bardoux – CFO
Tel: (33) 01 40 18 72 00

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

European Commission Grants New Indication for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG)21.8.2017 16:25Tiedote

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the European Commission (EC) approved the extension of the indication for Soliris® (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. Soliris is the first and only complement-based therapy approved in the European Union (EU) for this ultra-rare subset of patients.1-4 Patients with refractory gMG can have difficulties walking, talking, swallowing and breathing normally despite therapies currently used for MG. Exacerbations and crises of their disease may require hospitalization and intensive care and may be life-threatening.5-7 Soliris will be launched for this new indication initially in Germany, and Alexion is evaluating launches in additional EU countries. “Patients with refractory gMG have exhausted multiple the

IntegenX Applauds the Passage of the Rapid DNA Act of 201721.8.2017 15:00Tiedote

IntegenX Inc., the global market leader for Rapid DNA human identification, applauds the signing into law of S.139 and HR.510, The Rapid DNA Act of 2017. The legislation will allow law enforcement agencies, under standards and guidelines established by the FBI, to perform real-time DNA testing at time of arrest, within booking stations. Similar to how fingerprint analysis has evolved from a paper and ink practice to a point-of-action technology, DNA testing has now become possible in 90 minutes within a booking station, while a suspect is still in custody. With processing times reduced from weeks to less than two hours, the potential to identify or exonerate a suspect quickly will make a meaningful impact on law enforcement. IntegenX thanks U.S. Senate sponsor Senator Orrin Hatch (R-UT) and lead co-sponsor Senator Dianne Feinstein (D-CA) as well as House sponsor Congressman

PPG Completes COLORFUL COMMUNITIES Project at Primary School in Kecskemét, Hungary21.8.2017 11:03Tiedote

PPG (NYSE:PPG) today announced the completion of a COLORFUL COMMUNITIES™ project in Kecskemét, Hungary, that helped revitalize the learning environment of the Corvin Mátyás primary school. The Colorful Communities program provides PPG volunteers and products along with financial contributions to bring color and vitality to communities where the company operates around the world, such as in Kecskemét, where the PPG automotive service team operates with 33 employees. The project brought together more than 140 PPG and community volunteers who spent three days at the school revitalizing four classrooms, four changing rooms and the playground. PPG provided more than $20,000 to assist with the project, including more than 460 liters of Héra ® Prémium waterborne interior paint and Trinát ® Aqua wate

Glennmont Partners Completes Refinancing of Sleaford Biomass Plant for £150m21.8.2017 11:00Tiedote

Glennmont Partners has successfully completed the refinancing of the Sleaford Renewable Energy Plant on behalf of its dedicated clean energy fund, Glennmont Clean Energy Fund Europe I, as part of a programme of realisations of value from the Fund. Glennmont Partners is one of Europe’s largest fund managers focusing exclusively on investment in clean energy infrastructure. Glennmont raises long-term capital to invest in alternative power generation projects including wind farms, biomass power stations, solar parks and small-scale hydro power plants. The carefully selected, risk managed investments deliver sustained performance and predictable returns over periods of 10 years or more. Sleaford REP is a 40MWe straw-fired biomass plant located in Lincolnshire, UK. The plant has been in operation since 2014 and is being operated by Burmeister & Wain Scandinavian Contractor (BWSC). The

Boehringer Ingelheim: Advancing anticoagulation care with new data at ESC Congress 201721.8.2017 10:08Tiedote

Boehringer Ingelheim today announced that it will present important new data on the treatment of patients with atrial fibrillation (AF) at the ESC Congress in Barcelona, Spain, 26-30 August 2017. In total, four abstracts have been accepted, investigating different aspects of AF patient treatment. The results of the RE-DUAL PCI™ trial have been selected for one of the Late Breaking Science sessions of the congress. The RE-DUAL PCI™ trial compared dual therapy with triple therapy after percutaneous coronary intervention (PCI) with stent placement in approximately 2,500 adults with atrial fibrillation. Patients were either treated with dabigatran etexilate (Pradaxa®) and a single antiplatelet agent or with the vitamin K antagonist (VKA) warfarin and two antiplatelets. The dabigatran doses investigated in this trial are the same doses which have already demonstrated effective stroke preven

Study Investigates Performance of Masimo PVi® As Part of Goal-Directed Fluid Therapy During Laparoscopic Bariatric Surgery21.8.2017 09:00Tiedote

Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Firat University in Turkey evaluated the performance of Masimo PVi®, a noninvasive and continuous measurement of the dynamic changes in perfusion index (Pi) that occur during respiratory cycles, as the basis of a goal-directed fluid therapy (GDFT) protocol during laparoscopic bariatric surgery on mechanically-ventilated patients.1 In the study, Dr. Demirel and colleagues sought to evaluate whether using GDFT guided by PVi on morbidly obese patients undergoing laparoscopic Roux-en-Y gastric bypass (RYGB) surgery might result in less intravenous fluid use without compromising outcomes. They enrolled 60 patients and divided them randomly into control and GDFT groups. The control group’s fluid levels were managed by standard fluid therapy, using mean arterial pressure (MAP) and

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme